Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position

Stock Track

Feb 06

Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.

The clinical-stage immunology company reported a quarterly loss of $0.61 per share, which beat the analyst consensus estimate of $0.71 by 13.72%. This represents a 19.74% improvement over the loss of $0.76 per share from the same period last year. Additionally, the company's net loss of $110.64 million was better than the expected $125.06 million.

Immunovant also reported a strong cash position of $994.5 million as of December 31, 2025, which provides extended runway for its drug development programs. The company recently completed a $550 million financing round, further supporting the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track with topline data expected in 2026 and 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1150319145"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150319145\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150319145?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150319145","market":"hk","top_or_hot":-1,"title":"Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position","media":"Stock Track","content":"<p>Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.</p><p>The clinical-stage immunology company reported a quarterly loss of $0.61 per share, which beat the analyst consensus estimate of $0.71 by 13.72%. This represents a 19.74% improvement over the loss of $0.76 per share from the same period last year. Additionally, the company's net loss of $110.64 million was better than the expected $125.06 million.</p><p>Immunovant also reported a strong cash position of $994.5 million as of December 31, 2025, which provides extended runway for its drug development programs. The company recently completed a $550 million financing round, further supporting the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track with topline data expected in 2026 and 2027.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunovant Soars 7.40% in Pre-market on Better-Than-Expected Q3 Results and Strong Cash Position\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.</p><p>The clinical-stage immunology company reported a quarterly loss of $0.61 per share, which beat the analyst consensus estimate of $0.71 by 13.72%. This represents a 19.74% improvement over the loss of $0.76 per share from the same period last year. Additionally, the company's net loss of $110.64 million was better than the expected $125.06 million.</p><p>Immunovant also reported a strong cash position of $994.5 million as of December 31, 2025, which provides extended runway for its drug development programs. The company recently completed a $550 million financing round, further supporting the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track with topline data expected in 2026 and 2027.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMVT","symbol_name":"Immunovant, Inc.","start_time":0,"source_url":"","article_id":"1150319145","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150319145","pubTimestamp":1770383461,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.The clinical-stage immunology company reported a quarterly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMVT":"Immunovant, Inc."},"translate_title":"个股追踪|Immunovant盘前大涨7.40%，Q3业绩好于预期，现金状况强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":1},"content_text":"Immunovant, Inc. (IMVT) experienced a significant pre-market surge of 7.40% following the release of its third-quarter financial results.The clinical-stage immunology company reported a quarterly loss of $0.61 per share, which beat the analyst consensus estimate of $0.71 by 13.72%. This represents a 19.74% improvement over the loss of $0.76 per share from the same period last year. Additionally, the company's net loss of $110.64 million was better than the expected $125.06 million.Immunovant also reported a strong cash position of $994.5 million as of December 31, 2025, which provides extended runway for its drug development programs. The company recently completed a $550 million financing round, further supporting the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track with topline data expected in 2026 and 2027.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}